Unknown PHASE2 INTERVENTIONAL 1-arm NCT01016002

Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

Sponsor: Biolitec Pharma Ltd.

Conditions Non-curative Resectable Bile Duct Carcinoma

Interventions Temoporfin

Updated 4 times since 2017 Last updated: Nov 16, 2009 Started: Jan 31, 2006 Primary completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-curative Resectable Bile Duct Carcinoma, this trial is ongoing. The trial is conducted by Biolitec Pharma Ltd. and has accumulated 4 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biolitec Pharma Ltd.
University of Salzburg

Data source: University of Salzburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamburg, Germany
• Salzburg, Austria